A2

5. (Once amended) The method of claim 1, wherein the clioquinol is administered orally.

Please substitute the following claims 8-11 for currently pending claims 8-11:

8. (Once amended) The method of claim 1, further comprising administering trace metals with or subsequent to the administration of the clioquinol.

A3

9. (Once amended) The method of claim 1, wherein the clioquinol is administered parenterally.

10. (Once amended) The method of claim 1, wherein the clioquinol is administered intradermally.

11. (Once amended) The method of claim 1, wherein the therapy is carried out up to 10 years.

Cancel claim 2 without prejudice or disclaimer.

Add new claims 12-46:

--12. A method of treating a subject having or suspected of having Alzheimer's disease comprising administering to the subject an amount of clioquinol effective to treat Alzheimer's disease.

13. The method according to claim 12, wherein the clioquinol is (a) administered for one to 21 days, followed by (b) a period of one to four weeks during which clioquinol is not administered.

14. A method of treating a subject having or suspected of having Alzheimer's disease comprising administering to the subject an amount of clioquinol effective to increase the solubility of amyloid-beta in the cerebrospinal fluid of said subject.

15. A method of treating a subject having or suspected of having Alzheimer's disease comprising administering to the subject (a) an amount of clioquinol effective to treat or prevent Alzheimer's disease, and (b) an amount of vitamin B_{12}.

16. The method according to claim 15 wherein the amount of vitamin B_{12} is effective to inhibit a detrimental side effect of clioquinol administration.

17. The method according to claim 15 wherein a pharmaceutical composition comprising clioquinol is administered for one to 21 days, followed by a period of one to four weeks during which a pharmaceutical composition comprising vitamin B_{12} is administered and clioquinol is not administered.

18. The method according to claim 15 wherein the clioquinol and vitamin B_{12} are administered sequentially.

19. The method according to claim 15 wherein the clioquinol and vitamin B_{12} are administered substantially simultaneously.

20. The method according to claim 16 wherein a pharmaceutical composition comprising clioquinol is administered for one to 21 days, followed by a period of one to four weeks during which a pharmaceutical composition comprising vitamin B_{12} is administered and clioquinol is not administered.

21. The method according to claim 12, 14 or 15, wherein the subject is human.

22. The method according to claim 12 or 15, wherein the clioquinol is administered in an amount of 5-10 mg/kg body weight one to four times daily.

23. The method according to claim 12, wherein trace metals are administered together with or subsequent to the administration of clioquinol.

24. The method according to claim 12 or 15, wherein the clioquinol is administered intermittently.

25. The method according to claim 12, wherein the clioquinol is administered for up to ten years.

26. The method according to claim 12 or 15, wherein the clioquinol is formulated for oral administration.

27. The method according to claim 12 or 15, wherein the clioquinol is formulated for parenteral or intradermal administration.

28. The method according to claim 12 or 15, wherein the vitamin B_{12} is formulated for intramuscular administration.

29. The method according to claim 12 or 15, wherein the vitamin B_{12} is formulated for oral administration.

30. The method according to claim 15, 16 or 17, wherein the clioquinol and vitamin B_{12} are each purified.

31. A pharmaceutical composition comprising an amount of clioquinol effective to treat Alzheimer's disease, and vitamin B_{12}.

32. The pharmaceutical composition according to claim 31, which further comprises a pharmaceutically acceptable carrier.

33. The pharmaceutical composition according to claim 31, wherein the amount of clioquinol is 5-10 mg/kg body weight.

34. The pharmaceutical composition according to claim 31, wherein the amount of vitamin B_{12} is 7-10 mg/kg bodyweight.

35. The pharmaceutical composition according to claim 31, wherein the amount of vitamin B_{12} is 70-100 μg/kg bodyweight.

36. The pharmaceutical composition according to claim 31, wherein the composition is formulated for parenteral or intradermal administration.

37. The pharmaceutical composition according to claim 31, wherein the composition is formulated for oral administration.

38. The pharmaceutical composition according to claim 31 or 32, wherein the clioquinol and vitamin B_{12} are each purified.

39. A pharmaceutical composition comprising a therapeutically effective amount of clioquinol and vitamin B_{12}.

40. The pharmaceutical composition according to claim 39, which further comprises a pharmaceutically acceptable carrier.

41. The pharmaceutical composition according to claim 39, wherein the amount of clioquinol is 5-10 mg/kg body weight.

42. The pharmaceutical composition according to claim 39, wherein the amount of vitamin B_{12} is 7-10 mg/kg bodyweight.

43. The pharmaceutical composition according to claim 39, wherein the amount of vitamin B_{12} is 70-100 μg/kg bodyweight.

44. The pharmaceutical composition according to claim 39, wherein the composition is formulated for parenteral or intradermal administration.

45. The pharmaceutical composition according to claim 39, wherein the composition is formulated for oral administration.

46. The pharmaceutical composition according to claim 39 or 40, wherein the clioquinol and vitamin B_{12} are each purified.--